RSV

Using nose organoids, researchers have highlighted key differences between the infection by SARS-CoV-2 and that of respiratory syncytial virus.

The team also used their human nose organoid model of RSV infection to test the efficacy of palivizumab. This system also can be used to study other respiratory viruses and potentially other disease-causing microbes. The model also proved to be a useful tool to test the efficacy of therapeutics such as palivizumab, monoclonal antibody that has been approved by the US Food and Drug Association (FDA) to prevent severe RSV disease in high-risk infants.